Lori J. Wirth博士现任哈佛医学院副教授;于2008年加入麻省总医院，任头颈癌中心医学主任。

Wirth博士是头颈肿瘤领域的权威人士，在头颈部癌症的综合治疗方面颇有心得和经验，并为晚期甲状腺癌提供新的治疗方法。 她是负责指导癌症治疗和研究工作的国家和国际委员会成员。

【专长领域】

头颈部肿瘤、内分泌肿瘤、甲状腺癌、口咽癌、喉癌、鼻窦肿瘤

【教育背景】

1997年，毕业于哥伦比亚大学医学院，取得医学博士学位

2000年，于纽约长老会医院，完成住院医培训

哈佛大学丹娜法伯癌症研究院，完成血液/肿瘤专科培训

【学术著作】(摘选)

Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Thierauf J, Ramamurthy N, Jo VY, Robinson H, Frazier RP, Gonzalez J, Pacula M, Dominguez Meneses E, Nose V, Nardi V, Dias-Santagata D, Le LP, Lin DT, Faquin WC, Wirth LJ, Hess J, Iafrate AJ, Lennerz JK. Oncologist. 2019 Mar 29. pii: theoncologist.2018-0515.

Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.

Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D.

Clin Cancer Res. 2013 Jan 15;19(2):480-90.

Lubitz CC, Zhan T, Gunda V, Amin S, Gigliotti BJ, Fingeret AL, Holm TM, Wachtel H, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ, Parangi S. Circulating BRAFLevels Correlate with Treatment in Patients with Thyroid Carcinoma. Thyroid 2018. PubMed

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiukiewicz K, Thomas T, Nehs MA, Marqusee E, Lee SL, Janne PA, Lorch JH. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res 2018. PubMed

Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. J Clin Oncol 2017; 35:3315-3321. PubMed

Mattox A, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, Diefenbach TJ, Morris LG, Lin DT, Wirth LJ, Lefranc-Torres A, Ishida E, Chakravarty PD, Johnson L, Zeng Y, Chen H, Poznansky MC, Iyengar NM, Pai SI. PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4+ TILs in the presence of PD-L1+ TAMs. Cancer Res 2017. PubMed

Addison D, Seidelmann SB, Janjua SA, Emami H, Staziaki PV, Hallett TR, Szilveszter B, Lu MT, Cambria RP, Hoffmann U, Chan AW, Wirth LJ, Neilan TG. Human Papillomavirus Status and the Risk of Cerebrovascular Events Following Radiation Therapy for Head and Neck Cancer. J Am Heart Assoc 2017. PubMed

Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC, Lorch JH. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer 2017. PubMed